Navigation Links
Combined Molecular-targeted and Hormonal Therapies Offer Promise in Treating Ovarian Cancer

A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.

Several clinical trials have confirmed the role of hormone therapy in recurrent ovarian cancer treatment, especially in patients with low-grade tumors, says review author Dr. Siqing Fu, an assistant professor of oncology at the University of Texas at Houston. However, more research is needed to determine whether combining molecular-targeted therapy with hormonal therapy would be a more effective option.

Ovarian cancer is the deadliest of gynecological cancers; approximately 70 percent of patients are diagnosed in the later stages, when the 5-year survival rate drops below 25 percent. Traditional chemotherapy has proven to be generally ineffective against recurrent ovarian cancer, which has led researchers to investigate novel treatments.

While a cure is unlikely, the goals of treatment are to control tumor-related symptoms and to improve or maintain quality of life, says Dr. Fu. After surveying the latest research, combined molecular-targeted and hormonal therapy offers the greatest promise in achieving these goals and therefore deserves further investigation.


'"/>




Page: 1

Related medicine news :

1. Combined scan gives exact cancer diagnosis
2. A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss
3. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
4. Vision Loss in Elderly Caused By Combined Effect of Genes and Bacterium
5. Exercise Combined with Dialysis Yields Better Results
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. A Combined Heart Pill-developed by Dr. Reddy’
8. A Combined Research for Producing Chlamydia Vaccine Begins
9. Combined Ingredients may Cut Cholesterol Levels
10. Combined Imaging Approach may Provide Better Identification of Difficult-to-diagnose Brain Clots
11. Combined Imaging Approach may Be Effective in Diagnosing Some Brain Clots
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Senator Ben Nelson Puts U.S. Bishops' Interests Ahead of Americans' Healthcare Needs 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:Pitt study suggests craving hinders comprehension without your realizing it 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:Wellness Cruise Offers Crystal Guests 'Indian Ocean Insight' 2
Other Medicine Technology:Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 2Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 3Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 5